for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug

July 13 (Reuters) - A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals Inc to launch a generic version of the medicine.

The U.S. Court of Appeals for the Federal Circuit affirmed a series of rulings in favor of Amneal that the Jazz patents described obvious ideas.

Reporting by Jan Wolfe Editing by Chizu Nomiyama

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up